Tango Therapeutics, Inc.TNGXEarnings & Financial Report
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies and novel immunotherapies for patients with hard-to-treat cancers. Its core pipeline targets genetic vulnerabilities in tumor cells, with key programs targeting mutations common across multiple solid tumor types, serving global oncology populations via in-house R&D and industry partnerships.
TNGX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-41.9M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.29
Tango Therapeutics, Inc. Q4 FY2025 Financial Summary
Tango Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Tango Therapeutics, Inc. Annual Revenue by Year
Tango Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $62.4M).
Tango Therapeutics, Inc. Quarterly Revenue & Net Profit History
Tango Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $53.8M | +363.6% | $15.9M | 29.5% |
| Q2 FY2025 | $3.2M | -84.0% | $-38.9M | -1221.4% |
| Q1 FY2025 | $5.4M | -16.7% | $-39.9M | -739.5% |
| Q4 FY2024 | $4.1M | -24.2% | N/A | N/A |
| Q3 FY2024 | $11.6M | +8.2% | $-29.2M | -251.3% |
| Q2 FY2024 | $19.9M | +36.1% | $-25.6M | -128.6% |
| Q1 FY2024 | $6.5M | +12.2% | $-37.9M | -585.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $19.9M | $11.6M | $4.1M | $5.4M | $3.2M | $53.8M | $0 |
| YoY Growth | 12.2% | 36.1% | 8.2% | -24.2% | -16.7% | -84.0% | 363.6% | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $406.2M | $381.5M | $352.4M | $316.5M | $274.3M | $237.9M | $210.1M | $398.7M |
| Liabilities | $141.8M | $133.8M | $123.2M | $117.0M | $107.5M | $102.9M | $50.1M | $52.5M |
| Equity | $264.5M | $247.7M | $229.2M | $199.5M | $166.8M | $135.0M | $160.0M | $346.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37.9M | $-23.6M | $-33.4M | $-131.5M | $-41.7M | $-36.5M | $-31.0M | $-29.7M |